News SalvaRx Group plc

Equities

SALV

IM00BZ4SS228

Delayed London S.E. Other stock markets			5-day change	1st Jan Change
- ^GBX	-.--%		-47.06%	-.--%

2019	SalvaRx Evaluates Takeover Opportunities	CI
2019	Salvarx Group plc Reports Earnings Results for the Half Year Ended June 30, 2019	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SalvaRx : Portage Issues Common Shares and Warrants in Settlement of SalvaRx Loan Note Obligations	20-10-14	AQ
SalvaRx : Half Yearly Report 30 June 2019 RNS	19-09-27	PU
SalvaRx : RNS SalvaRx Group PLC interim report 30 June 2019	19-09-26	PU
SalvaRx Evaluates Takeover Opportunities	19-09-26	CI
Salvarx Group plc Reports Earnings Results for the Half Year Ended June 30, 2019	19-09-26	CI
Salvarx Group plc Reports Earnings Results for the Full Year Ended December 31, 2018	19-06-28	CI
Portage Biotech Inc. (OTCPK:PTGE.F) completed the acquisition of SalvaRx Limited from SalvaRx Group plc, James Mellon and Greg Baile.	19-01-07	CI
SalvaRx Group plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018	18-09-27	CI
Portage Biotech Inc. (OTCPK:PTGE.F) (‘Portage’) entered into a conditional sale agreement to acquire SalvaRx Limited from SalvaRx Group plc, James Mellon and Greg Baile for $80.5 million.	18-08-13	CI
SalvaRx Group plc Announces Consolidated Earnings Results for the Year Ended December 31, 2017	18-06-28	CI
SalvaRx Seeks Acquisitions	18-06-28	CI
SalvaRx Announces an Unsecured $1 Million Loan	18-06-26	CI
SalvaRx Group plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2017	17-09-27	CI
SalvaRx Group plc Announces Final Audited Consolidated Earnings Results for the Year Ended December 31, 2016	17-06-30	CI
SalvaRx Seeks Investments	17-06-30	CI
SalvaRx Group plc Treats First Patient INT230-6 as Part of A Phase 1/2 International Clinical Study	17-05-30	CI
SalvaRx Group plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2016	16-09-13	CI
Salvarx Group plc Announces Audited Consolidated Earnings Results for the Year Ended 31 December 2015	16-06-27	CI
SalvaRx Seeks Acquisitions	16-06-27	CI
Intensity Therapeutics, Inc. announced that it has received $10 million in funding from Batterson Venture Capital, LLC, Vcapital, Inc., Seed Innovations Limited, SalvaRx Group plc	16-06-25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News SalvaRx Group plc

Equities

SALV

IM00BZ4SS228

Summary

Filters